Compare AbbVie Inc (ABBV) vs BHP Billiton Limited (BHP) Price & Performance

AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.

The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.

BHP trades at $80.23, down 3.72% over the past 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2025 EPS of $2.12, beating expectations, but missed in Q4 2025. Recent news includes a $2.3 billion writedown at the Jansen potash project and leadership changes under incoming CEO Brandon Craig. Financials show strong profitability with an 18.97% net income margin and $20.67B in operating cash flow for 2024.

BHP's outlook is supported by robust cash flows and strategic focus on copper, but faces risks from cost overruns and labor disputes. Analyst consensus is mixed with 22.58% buy ratings. The stock presents a value opportunity with a P/E of 20.77, though investors should monitor execution on growth projects and commodity price volatility.